Effects of Intrauterine Administration of Autologous PBMC on the Endometrial Cells Populations

Launched by NADEZHDA WOMEN'S HEALTH HOSPITAL · Jun 13, 2022

Keywords

ClinConnect Summary

This clinical trial is studying how a specific treatment, called autologous PBMC (which are immune cells taken from the patient’s own blood), can improve the lining of the uterus (endometrium) in women who are having difficulty getting pregnant. The researchers believe that the way these immune cells communicate might play a big role in whether an embryo can successfully implant in the uterus. By analyzing the changes in the types of cells in the endometrium after this treatment, the study aims to see if it can lead to better outcomes in assisted reproductive techniques, like in vitro fertilization (IVF).

To participate in this trial, women must meet certain criteria, such as having primary infertility, regular menstrual cycles, and being involved in assisted reproduction treatment with healthy embryos. However, those with specific conditions, like uterine diseases or certain autoimmune disorders, cannot join. If eligible, participants will receive the treatment and be monitored for how it affects their endometrial cell composition and IVF success rates. This study could provide valuable insights into improving fertility treatments for women struggling to conceive.

Gender

FEMALE

Eligibility criteria

• Inclusion Criteria:
• • Participating in Assisted Reproduction Treatment
• • Presenting altered endometrial immune profile
• • Having primary infertility
• • Having regular menstrual cycles
• • Embryo transfer of euploid embryos
• Exclusion Criteria:
• • Uterine pathologies
• • Endometrial Bacterial infections
• • Active endometrial inflammation
• • Polycystic ovary syndrome
• • Presence of auto anti-bodies such as anti-TPO, anti-TG, ACA, APA, ANA, and anti-dsDNA
• • Presence of mutations involving the coagulation system such as deficiency of factor XII, Pro C, Pro S
• • Cancer diagnostics
• • Positive HIV, HCV or HBV tests